Welcome to the Office of Cancer Survivorship Program, DCCPS
The NCI Office of Cancer Survivorship (OCS) works to enhance the quality and length of survival of all persons diagnosed with cancer and to prevent, minimize, or manage adverse effects of cancer and its treatment.
![Twitter icon, opens in a new window](/sites/default/files/inline-images/twitter_icon_2x.png)
Stay up-to-date on everything from OCS @NCICancerSurv
![linkedin icon](/sites/default/files/inline-images/linkedin_icon_2x.png)
Stay up-to-date on everything from DCCPS LinkedIn
Spotlight
Request for Information
NCI announces NOT-CA-24-061, Seeking Input to Identify and Explore Experiences Utilizing the Whole Person Perspective and Evidence for Its Value in the Care of People with Cancer. Read more about this RFI.
Upcoming Presentation
September 2024 – Join the NCI Office of Cancer Survivorship for this OCS Director’s Series webinar on September 17, 2024, from 2-3 p.m. ET. Dr. Frank J. Penedo will present Implementing Patient-Reported Outcomes and Psychosocial Interventions in Diverse Communities of Cancer Survivors, and advocate and survivor Iliana Suarez will share her experiences. Register now.
Publication
In this recent publication in JNCI, Dr. Michelle Doose and coauthors examined the FY2017-22 NIH Cancer Survivorship Research Portfolio to determine whether survivorship research focused on populations experiencing health disparities has shifted from describing health disparities to a health equity research agenda that addresses structural drivers. Read more.
Funding Opportunities
About The Office of Cancer Survivorship
An individual is considered a cancer survivor from the time of diagnosis, through the balance of life. There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to capture a population of those with a history of cancer rather than to provide a label that may or may not resonate with individuals.
OCS works to promote a better understanding of unique needs of the growing population of cancer survivors, and to enhance our ability to address them.
Quick Links
Featured Graph and Statistic
Individuals Living with Metastatic Cancer
![Estimated numbers of individuals living with metastatic cancer in the U.S. on January 1, 2018, by cancer type, and percentage by cancer type who were diagnosed with metastasis de novo versus with early-stage disease that progressed to metastatic disease. Numbers above each bar represent total estimated metastatic prevalence for each cancer type. De novo percentages are: Bladder 71.8% of 15,767, Breast 61.4% of 140,230, Colon and Rectum 43.9% of 133,234, Lung and Bronchus 30.3% of 174.090, Melanoma 69.8% of 38,716, and Prostate 55.0% of 120,368.](/sites/default/files/2022-09/2022_Individuals_Living_with_Metastatic_Cancer_1000x770-2.png)
Researchers at the National Cancer Institute have estimated that 623,405 people in the United States were living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma as of 2018, and that number is expected to increase to 693,452 by the year 2025.
Cancer Survivor Statistics
![18.1 million survivors](/sites/default/files/2022-06/16million-cancer-survivors.jpg)
It is estimated that there are 18.1 million cancer survivors in the United States. This represents approximately 5.4% of the population.